首页> 美国卫生研究院文献>Journal of Nucleic Acids >Alternative Splicing in Oncogenic Kinases: From Physiological Functions to Cancer
【2h】

Alternative Splicing in Oncogenic Kinases: From Physiological Functions to Cancer

机译:致癌激酶的替代剪接:从生理功能到癌症。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Among the 518 protein kinases encoded by the human kinome, several of them act as oncoproteins in human cancers. Like other eukaryotic genes, oncogenes encoding protein kinases are frequently subjected to alternative splicing in coding as well as noncoding sequences. In the present paper, we will illustrate how alternative splicing can significantly impact on the physiological functions of oncogenic protein kinases, as demonstrated by mouse genetic model studies. This includes examples of membrane-bound tyrosine kinases receptors (FGFR2, Ret, TrkB, ErbB4, and VEGFR) as well as cytosolic protein kinases (B-Raf). We will further discuss how regular alternative splicing events of these kinases are in some instances implicated in oncogenic processes during tumor progression (FGFR, TrkB, ErbB2, Abl, and AuroraA). Finally, we will present typical examples of aberrant splicing responsible for the deregulation of oncogenic kinases activity in cancers (AuroraB, Jak2, Kit, Met, and Ron).
机译:在人类激酶中编码的518种蛋白激酶中,有几种在人类癌症中起癌蛋白的作用。像其他真核基因一样,编码蛋白激酶的癌基因经常在编码和非编码序列中经历选择性剪接。在本文中,我们将说明替代剪接如何对致癌蛋白激酶的生理功能产生重大影响,正如小鼠遗传模型研究所证明的那样。这包括膜结合酪氨酸激酶受体(FGFR2,Ret,TrkB,ErbB4和VEGFR)以及胞质蛋白激酶(B-Raf)的实例。我们将进一步讨论在某些情况下,这些激酶的常规选择性剪接事件与肿瘤进展期间的致癌过程有关(FGFR,TrkB,ErbB2,Abl和AuroraA)。最后,我们将介绍导致癌症中致癌激酶活性失控的异常剪接的典型示例(AuroraB,Jak2,Kit,Met和Ron)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号